Glycolysis Inhibitors for Anticancer Therapy: A Review of Recent Patents

Title:Glycolysis Inhibitors for Anticancer Therapy: A Review of Recent Patents

Volume: 11 Issue: 3

Author(s): Huaming Sheng and Weijuan Tang

Affiliation:

Keywords: Cancer, glycolysis, glycolytic enzymes, inhibitors, metabolic pathway, warburg effect.

Abstract: Background: The aerobic glycolysis in tumor cells known as Warburg effect is one of the most important hallmarks of cancer. It is proposed that the upregulation of the series of metabolic enzymes along the glycolytic pathway may contribute to the Warburg effect.

Objectives: The inhibition of these glycolytic enzymes has been found to be a novel strategy for anticancer treatment. This review summaries recent patents in the development of small molecule inhibitors for the key enzymes in tumor glycolysis. The targeted enzymes are GLUTs, HKs, PFK, PGAM1, PKM2, LDHA, MCTs and PDK.

Conclusion: Although most inhibitors are still in the preclinical phase, the inhibition of glycolytic enzymes represents a very promising approach for anticancer treatment. The future development could be more focused on the discovery of new metabolic enzyme that is specifically expressed in tumor cells.

Cite this article as:

Sheng Huaming and Tang Weijuan, Glycolysis Inhibitors for Anticancer Therapy: A Review of Recent Patents, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (3) . https://dx.doi.org/10.2174/1574892811666160415160104